•  
  •  
 

Turkish Journal of Biology

Author ORCID Identifier

AYCA NEZİR: 0000-0001-8229-1865

ZEYNEP BOLAT: 0000-0002-9216-6336

ONGUN SAKA: 0000-0002-8726-6391

ITIR ZEMHERİ: 0000-0003-0247-0332

SEVGİ GÜLYÜZ: 0000-0002-2576-3085

UMUT ÖZKÖSE: 0000-0003-4807-6322

ÖZGÜR YILMAZ: 0000-0003-3892-2775

ASUMAN BOZKIR: 0000-0002-2782-3280

FİKRETTİN ŞAHİN: 0000-0003-1503-5567

DİLEK TELCİ: 0000-0002-2793-6533

DOI

10.55730/1300-0152.2693

Abstract

BackgroundNanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer.MethodsPoly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with BikDDA, a mutant form of the proapoptotik Bik. We selected 22Rv1 cells with moderate upregulation of PSMA to test the in vitro uptake, cell death, and in vivo anti-cancer activity of our formulation, P563-PEtOx-DOPE-BikDDA.ResultsBikDDA was upregulated in 22Rv1 cells, inducing cell death, and CD-1 nude mice xenografts administered with the formulation showed significant tumor regression.ConclusionWe suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.

Keywords

BikDDA, Liposome, Peptide 563, Poly(2-ethyl-2-oxazoline), Prostate cancer, Targeted gene therapy

First Page

174

Last Page

181

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Included in

Biology Commons

Share

COinS